As panel backs Moderna booster, broader concerns still in play

As an FDA advisory panel digested a small trial size and lack of diversity in Moderna’s data, the group’s unanimous support of Moderna’s booster shots in high-risk groups highlights how the pandemic’s urgency still drives a departure from business as usual.

Members of FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) did draw a clear line on the insufficiency of evidence backing boosters for lower risk populations.   ...